SynthesisFrontiers in medicine2026
Qingke Pingchuan granules as adjuvant therapy for acute exacerbation of chronic obstructive pulmonary disease, acute exacerbation asthma, and acute bronchitis: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD), Acute Exacerbation of Asthma(AEA), and acute bronchitis (AB) are known as the common acute airway inflammatory illnesses. This study seeks to systematically assess the effective rate and safety of Qingke Pingchuan Granules (QKPC) in treating these three illnesses in order to give evidence-based recommendations for therapeutic practice. Methods: Web of Science, PubMed, Cochrane Library, Elsevier ScienceDirect, CNKI, Wanfang Data, and VIP databases were all thoroughly scoured between their creation and November 2025. Leveraging the Cochrane Risk of Bias tool, two reviewers independently sifted through the reports, retrieved study data, and assessed the methodological rigor. RevMan 5.4 and Stata 17.0 software were used for statistical analyses, and effect sizes were reported as RR or MD with 95% CIs. The Cochrane Q test and the I Results: 21 RCTs with 2087 individuals were incorporated into this study. The findings demonstrated that QKPC in conjunction with conventional treatment considerably improved clinical outcomes, including overall response rate, FEV₁%, and FVC, as compared to conventional Western medicine alone. Additionally, it decreased the inflammatory factor (CRP). QKPC significantly improved the CAT score, mMRC score, 6MWT distance, and PaO₂ for AECOPD-specific outcomes (all Conclusion: In patients with AECOPD, AEA, and AB, QKPC in conjunction with traditional Western medicine treatment can dramatically enhance clinical efficacy, lung function, and inflammatory status without raising the risk of adverse reactions. For these acute airway inflammatory illnesses, it is a safe and effective adjuvant therapy alternative that indicated to significantly improve symptoms, lung function, and quality of life in individuals with AECOPD. Systematic review registration: Unique Identifier (CRD420251229191), (https://www.crd.york.ac.uk/PROSPERO/view/CRD420251229191).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.